Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap - LARVOL DELTA

Interventions for Migraine and Sleep: A Systematic Review Exploring Their Bidirectional Association. (PubMed, Eur J Neurol) - "Integrated approaches combining migraine and sleep interventions show promise for symptom management. Further research is needed to refine treatment strategies and assess long-term effects."

Clinical • Journal • Review • CNS Disorders • Insomnia • Migraine • Pain • Sleep Disorder

Effects of low-dose botulinum toxin for the treatment of spastic children with cerebral palsy (PubMed, Tunis Med) - "There is not yet a uniform strategy for TBA treatment in childre with CP and the doses used in the literature vary considerably over the years. It thus appears that the doses we use are within the range of the recommandations but remain by far lower than the doses used in the literature."

Journal • Retrospective data • Cerebral Palsy • CNS Disorders

Serum Sickness After Cosmetic Botulinum Toxin Type A Injections. (PubMed, Aesthet Surg J Open Forum) - "This case report and literature review demonstrates a novel case of serum sickness following cosmetic Botox® (onabotulinumtoxin-A, Allergan Aesthetics, an AbbVie company, Irvine, CA) administration, categorizes hypersensitivity reactions according to the Gell and Coombs classification (Types I-IV), explores the role of complexing proteins and formulation excipients, and highlights emerging clinical concerns. This will underscore the need for greater vigilance in identifying systemic immune responses to BoNT-A especially within the cosmetic medicine industry. Level of Evidence: 5 (Therapeutic)."

Journal • Aesthetic Medicine • Dermatology • Immunology

Chronic migraine prophylaxis: Comparative study between ultrasound-guided greater occipital nerve block and medical treatment. (PubMed, Clin Neurol Neurosurg) - "All studied interventions were effective. OnabotulinumtoxinA (via both GONB and PREEMPT injection) provided the most rapid and substantial benefit, while monoclonal antibodies provided progressive, sustained improvement."

Journal • Anesthesia • CNS Disorders • Migraine • Pain • Psychiatry

Safety Outcomes After Concomitant HOLEP and Botox: A Retrospective Cohort Study (OUS 2026) - No abstract available

Retrospective data

Commentary on "Onabotulinum Toxin A Is a Viable Intervention for Bladder Neck Obstruction in Women: A Prospective Pilot Study of Patient-Reported Outcomes". (PubMed, Neurourol Urodyn) - No abstract available

Journal

EMG-guided Botox Injection Versus Conventional Botox Injection in Gummy Smile Patients (clinicaltrials.gov) - P=N/A | N=32 | Recruiting | Sponsor: Cairo University | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2024 ➔ Aug 2026 | Trial primary completion date: Jun 2024 ➔ Jun 2026

Enrollment open • Trial completion date • Trial primary completion date

Relaxing Environment Lowers Anxiety During Chemodenervation: a Randomized Trial. (PubMed, Urogynecology (Phila)) - "A relaxing environment of lavender aromatherapy, calming music, and dim lighting is a noninvasive, easily implemented technique to decrease patients' anxiety before office intradetrusor chemodenervation."

Clinical • Journal • Mood Disorders • Overactive Bladder • Pain • Psychiatry

The Underestimated Burden of Urgency Urinary Incontinence Borne by Older Women. (PubMed, Urogynecology (Phila)) - "UI causes a constant and profound burden and loss that affects emotional, physical, and relational domains of life. However, older women resiliently seek ways to overcome the havoc UI creates across all areas of life."

Clinical • Journal • Urinary Incontinence • Urology

Public Search Interest in Aesthetic Procedures: Med Spas vs Dermatologists (AAD 2026) - "Procedures included Botox® injections, laser hair removal, chemical peels, laser skin resurfacing, microdermabrasion, microneedling, and dermal fillers...This trend may reflect shifting perceptions of cosmetic treatments as routine wellness services rather than medical interventions. Continued attention to patient education and regulatory oversight are needed."

Aesthetic Medicine • Inflammatory Arthritis

Mesotherapy and Botox for Non-Scarring Hair Loss (AAD 2026) - No abstract available

Alopecia

Enhanced Effectiveness of Onabotulinum Toxin A in Combination With Definisse KP1 Eye Contour Cream for Upper Face Rejuvenation: A Case Series. (PubMed, J Cosmet Dermatol) - "From this case series, the application of Definisse KP1 eye contour cream seems to enhance the effect of onabotulinum toxin A injection on periocular wrinkles and provide additional benefits in skin quality; the combined procedure was tolerated, feasible, and appreciated by subjects."

Journal • Aesthetic Medicine • Dermatology • Immunology

Peptides in facial plastic surgery: emerging applications in aesthetics and rejuvenation. (PubMed, Facial Plast Surg) - "Peptides are commonly classified as signal peptides, carrier peptides, and neurotransmitter-inhibiting "botox-like" peptides based on their proposed mechanisms of action...As patient interest grows, facial plastic surgeons are more frequently asked about the role, safety, and efficacy of peptide-based products. This article presents current evidence and proposed mechanisms to help guide informed discussions and clinical decision-making in facial plastic surgery practice."

Clinical • Journal

Urinary Cytokines in Predicting Intradetrusor Onabotulinumtoxin-A Response. (PubMed, Neurourol Urodyn) - "Asymptomatic bacteriuria does not affect Onabotulinumtoxin-A response. Older women were less likely to respond to Onabotulinumtoxin-A treatment and experienced a differential impact of inflammatory cytokines."

Journal • Inflammation • Overactive Bladder

Thermal Stability of Botulinum Toxin Type A Formulations Exposed to Heat In Vitro, Assessed by an In Vivo Mouse Potency Bioassay. (PubMed, Aesthet Surg J Open Forum) - "This study investigated the thermal stability of 4 commercial botulinum toxin type A (BoNT/A) products under conditions simulating EBD-related heat exposure, which includes 1 liquid formulation (INNOTOX, Medytox, Seoul, South Korea; hereafter referred to as innoBoNT/A) and 3 powder formulations: onabotulinumtoxinA (onaBoNT/A, BOTOX, Allergan, an Abbvie company, North Chicago, IL), incobotulinumtoxinA (incoBoNT/A, XEOMIN, Merz, Frankfurt, Germany), and abobotulinumtoxinA (aboBoNT/A, DYSPORT, Ipsen, Boulogne-Billancourt, France). In particular, onaBoNT/A showed a 32% decrease upon exposure at 60°C for 25 min and a complete loss of measurable potency at when exposed at 60°C for 40 min. Among the BoNT/A formulations evaluated, only the liquid-stabilized preparation preserved potency during thermal stress."

Journal • Preclinical

Negotiations with participating drug companies will occur in 2026 and any negotiated and renegotiated prices will become effective January 1, 2028. (CMS Press Release) - "The selected drug list for the third cycle of negotiations is: Anoro Ellipta...Botox; Botox Cosmetic; Cimzia; Cosentyx; Entyvio...Orencia...Trulicity....Xeljanz; Xeljanz XR; Xolair."

Medicare • Allergy • Ankylosing Spondylitis • Asthma • Chronic Obstructive Pulmonary Disease • Crohn's disease • Idiopathic Arthritis • Immunology • Migraine • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Ulcerative Colitis

Treatment-Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet-Rich Plasma in Bladder Pain Syndrome. (PubMed, Low Urin Tract Symptoms) - "Treatment-specific models combining clinical, urodynamic, and urinary biomarker data provide mechanistic insight into heterogeneous response profiles to BoNT-A and PRP in females with BPS. While these models may inform future phenotype-guided research and prospective validation, external validation is required before broader clinical implementation."

Biomarker • Journal • Retrospective data • Interstitial Cystitis • Musculoskeletal Pain • Pain

ETS4: Botulinum Toxin A vs Strabismus Surgery for Esotropia (clinicaltrials.gov) - P3 | N=244 | Not yet recruiting | Sponsor: Jaeb Center for Health Research

New P3 trial • Ophthalmology • Strabismus

Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Henry Ford Health System | Trial completion date: Dec 2025 ➔ Dec 2026

Trial completion date

Cost Comparison of Office-Based and Operating Room Intradetrusor OnabotulinumtoxinA Injections for Overactive Bladder (AUA 2026) - No abstract available

HEOR • Reimbursement • US reimbursement • Overactive Bladder

Managing the unexpected: Incidental appendicolithotomy during robotic Mitrofanoff with concurrent bladder onabotulinumtoxinA and cecostomy tube placement (AUA 2026) - No abstract available

Pediatrics

Safety Outcomes after Concomitant HOLEP & Botox: A Retrospective Cohort Study (AUA 2026) - No abstract available

Retrospective data • Benign Prostatic Hyperplasia

Urinary Retention Following Combined Intradetrusor OnabotulinumtoxinA and Urethral Bulking with Bulkamid for Mixed Urinary Incontinence: A Single Institution Experience (AUA 2026) - No abstract available

Clinical • Urinary Incontinence • Urology

Intradetrusor OnabotulinumtoxinA is Safe and Effective in Men with Overactive Bladder following Radical Prostatectomy or Outlet Surgery (AUA 2026) - No abstract available

Surgery • Overactive Bladder • Prostate Cancer

Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder (AUA 2026) - No abstract available

Adverse events • Clinical • Overactive Bladder